Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test could decide who needs stronger or milder chemo for colorectal cancer

NCT ID NCT07340567

Ongoing Knowledge-focused Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can help doctors choose the right amount of chemotherapy for people with stage III colorectal cancer. About 2,450 participants will be split into groups based on their ctDNA results: those with negative ctDNA may receive a milder chemo (capecitabine alone) instead of standard treatment, while those with positive ctDNA may get a stronger combo (FOLFIRINOX) instead of the usual FOLFOX. The goal is to see if this personalized approach can improve disease-free survival without causing unnecessary side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Capecitabine, Oxaliplatin, FOLFIRINOX, FOLFOX
What this could lead to
If successful, this could show that a simple blood test can guide whether patients need stronger or milder chemotherapy, reducing side effects for some and improving outcomes for others.
What could go wrong
This is a large phase 3 trial, but it is not yet recruiting. The approach relies on ctDNA testing, which may not be perfectly accurate, and the benefits or risks of intensifying or de-escalating treatment are still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer colorectal carcinoma colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER

Contacts and locations

Locations

  • Institut Gustave Roussy

    Villejuif, 94800, France

  • Onkologikliniken

    Uppsala, 75185, Sweden

  • Sahlgrenska University Hospital

    Gothenburg, 41345, Sweden

  • Skäne University Hospital

    Lund, 22185, Sweden

  • Södersjukhuset

    Stockholm, 11883, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.